溶瘤病毒
溶癌病毒
医学
临床试验
免疫疗法
胶质瘤
脑瘤
肿瘤科
癌症
免疫学
内科学
病理
癌症研究
作者
Gelare Ghajar-Rahimi,Kyung-Don Kang,Stacie K. Totsch,Sam E. Gary,Abbey Rocco,Sarah E. Blitz,Kara Kachurak,M. R. Chambers,Rong Li,Elizabeth A. Beierle,Asim Bag,James M. Johnston,James M. Markert,Joshua D. Bernstock,Gregory K. Friedman
标识
DOI:10.1016/j.pharmthera.2022.108193
摘要
Malignant brain tumors constitute nearly one-third of cancer diagnoses in children and have recently surpassed hematologic malignancies as the most lethal neoplasm in the pediatric population. Outcomes for children with brain tumors are unacceptably poor and current standards of care-surgical resection, chemotherapy, and radiation-are associated with significant long-term morbidity. Oncolytic virotherapy has emerged as a promising immunotherapy for the treatment of brain tumors. While the majority of brain tumor clinical trials utilizing oncolytic virotherapy have been in adults, five viruses are being tested in pediatric brain tumor clinical trials: herpes simplex virus (G207), reovirus (pelareorep/Reolysin), measles virus (MV-NIS), poliovirus (PVSRIPO), and adenovirus (DNX-2401, AloCELYVIR). Herein, we review past and current pediatric immunovirotherapy brain tumor trials including the relevant preclinical and clinical research that contributed to their development. We describe mechanisms by which the viruses may overcome barriers in treating pediatric brain tumors, examine challenges associated with achieving effective, durable responses, highlight unique aspects and successes of the trials, and discuss future directions of immunovirotherapy research for the treatment of pediatric brain tumors.
科研通智能强力驱动
Strongly Powered by AbleSci AI